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Abstract: Deposition of soluble proteins as insoluble amyloid fibrils is associated with a number of
pathological states. There is a growing interest in the identification of small molecules that can prevent
proteins from undergoing amyloid fibril formation. In the present study, a series of small aromatic
compounds with different substitutions of 1,3,5-triphenylbenzene have been synthesized and their
possible effects on amyloid fibril formation by hen egg white lysozyme (HEWL), a model protein
for amyloid formation, and of their resulting toxicity were examined. The inhibitory effect of the
compounds against HEWL amyloid formation was analyzed using thioflavin T and Congo red binding
assays, atomic force microscopy, Fourier-transform infrared spectroscopy, and cytotoxicity assays,
such as the 3-(4,5-Dimethylthiazol)-2,5-Diphenyltetrazolium Bromide (MTT) reduction assay and
caspase-3 activity measurements. We found that all compounds in our screen were efficient inhibitors
of HEWL fibril formation and their associated toxicity. We showed that electron-withdrawing
substituents such as –F and –NO2 potentiated the inhibitory potential of 1,3,5-triphenylbenzene,
whereas electron-donating groups such as –OH, –OCH3, and –CH3 lowered it. These results may
ultimately find applications in the development of potential inhibitors against amyloid fibril formation
and its biologically adverse effects.
Keywords: protein misfolding; HEWL amyloid aggregation; drug discovery; small aromatic
compounds; amyloid inhibitors; triphenylbenzene
1. Introduction
The conversion of peptides or proteins from a soluble state into insoluble, β-sheet rich, fibrillar
aggregates, generally called amyloid fibrils, is a key event in a large family of human pathologies,
including neurodegenerative and non-neuropathic systemic amyloidosis [1,2]. Among these,
Alzheimer’s disease (AD) is the most known and diffuse and it has an increasing incidence in
the worldwide population. Similarly, Parkinson’s disease (PD), as well as Huntington’s, prion
diseases, type II diabetes, and systemic amyloidosis share the common hallmark of amyloid fibrillar
aggregates [1–3]. Although the proteins that comprise these deposits do not share any sequence
or structural homology, amyloid fibrils formed by different proteins share similar structural and
physicochemical properties and, possibly, a common pathogenic mechanism [4,5]. These diseases
involve self-assembly of soluble proteins into large insoluble fibrils through nucleation-dependent
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assembly, often via the formation of oligomeric structures that possess toxic properties [1,6,7]. Therefore,
preventing oligomer and fibril formation appears an attractive approach to tackling the progress of
such diseases.
Fibril formation is a polymerization process which can be simply described by a sigmoid curve
with three phases, originally suggested to be a three-stage process consisting of nucleation, fibril
elongation, and the final plateau [8], although the most recent progress has elucidated that each of
the three phases involve a combination of the various microscopic steps [9,10]. Despite intensive
efforts to treat amyloid-associated diseases, there is no fully effective and definitive treatment of
such diseases [1,2,11,12]. Several strategies have been undertaken in the attempt to interfere with
the formation and deposition of amyloid fibrils and their pathogenic role, including inhibition of the
formation of the amyloidogenic form of proteins by stabilization of the native conformation, reduction
in the production of the amyloidogenic sequence from a more complex protein, inhibition of protein
self-assembly in oligomers and fibrils, and enhancement in the clearance of toxic aggregates [13–17].
The propensity of proteins and peptides to form amyloid fibrillar structures is correlated to
their physicochemical properties such as net charge, secondary structure tendency, hydrophobicity,
and aromatic interactions [18,19]. Regions of the sequence of proteins promoting amyloid fibril
formation are often enriched with aromatic residues [20–22]. There are different hypotheses on
the precise role of the aromatic residues in the amyloidogenic process. One of them suggests that
aromatic amino acid residues promote peptide self-assembly for their hydrophobic nature, high β-sheet
propensity and null charge, along with their planar geometry that are the most relevant factors in
self-assembly [23–27]. According to this hypothesis, the aromatic nature of these residues does not
contribute significantly to their amyloidogenicity. Other various studies suggest that aromatic amino
acids contribute to peptide self-assembly through pi-stacking interactions [22,28,29]. Other groups also
believed that both hydrophobicity and aromaticity play a role in the self-assembly [30]. Regardless
of the precise mechanism by which aromatic residues drive amyloid fibril formation, the parallel
in-register alignment of β-strands in amyloid fibrils contributes to create a stacking of aromatic rings
along the fibril axis. Thus, aromatic compounds may competitively interact with aromatic residues in
amyloidogenic proteins, preventing their stacking, and block the self-assembly process [31]. It has
been found that the effect of aromatic compounds on amyloid aggregation strongly depends on their
structure and functional groups [32,33]. Multiple studies have reported that the number of phenyl
rings and electron-withdrawing or -donating groups on the molecules, as well as their positions, are
important characteristics that determine the effectiveness of the aromatic compounds in their inhibition
of Aβ aggregation [34–36]. Following this concept, six aromatic molecules belonging to the category
of 1,3,5-triphenylbenzene and having different electron-donor or -withdrawing substituents, have
been synthesized and their possible effects on amyloid fibril formation by a sample protein have been
tested. As a sample protein we have chosen hen egg white lysozyme (HEWL), as it is known to form
amyloid fibrils under appropriate conditions [37–40] and because the properties of the resulting fibrils
and the of the overall amyloid formation process have been investigated to a significant extent [41,42].
The effects of the compounds on amyloid fibril formation by HEWL and on the biological properties
of the resulting aggregates have been investigated through the use of various techniques, including
Congo red (CR) and thioflavin T (ThT) assays, Fourier-transform infrared (FTIR) spectroscopy, atomic
force microscopy (AFM), the MTT reduction assay, and caspase activity measurements. Our results
showed the importance of the substituents on the efficiency of aromatic compounds, with compounds
containing electron-withdrawing substituents having greater efficacy in HEWL amyloid inhibition,
thus representing promising compounds for developing inhibitors of amyloid fibril formation.
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2. Results
2.1. Chemistry of the Compounds
Scheme 1 shows a general formula for the preparation of some para-substituted
1,3,5-triphenylbenzenes (compounds 1–6). These pharmaceutical important compounds are made
by the condensation of aryl methyl ketones catalyzed by HPA/NCP under solvent-free conditions.
Nanoclinoptilolite (NCP) refers to a natural zeolite composed of a microporous arrangement of silica and
alumina and also HPA (H6P2W18O62) refers to the Wells–Dawson heteropolyacid. The heteropolyacid
catalyst activates the carbonyl group toward the electrophilic substitution. Using this procedure, six
compounds belonging to the category of para-substituted 1,3,5-triarylbenzenes have been synthesized
and purified as previously described [43,44]. These are 1,3,5-triphenylbenzene (Compound 1);
1,3,5-tris(4-fluorophenyl)benzene (Compound 2); 1,3,5-tris(4-nitrophenyl)benzene (Compound 3);
1,3,5-tris(4-methylphenyl)benzene (Compound 4); 1,3,5-tris(4-methoxyphenyl)benzene (Compound 5);
and 1,3,5-tris(4-hydroxyphenyl)benzene (Compound 6).
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 3 of 19 
 
condensation of aryl methyl ketones catalyzed by HPA/NCP under solvent-free conditions. 
Nanoclinoptilolite (NCP) refers to a natural zeolite composed of a microporous arrangement of silica 
and alumina and also HPA (H6P2W18O62) refers to the Wells–Dawson heteropolyacid. The 
heteropolyacid catalyst activates the carbonyl group toward the electrophilic substitution. Using this 
procedure, six compounds belonging to the category of para-substituted 1,3,5-triarylbenzenes have 
been synthesized and purified as previously described [43,44]. These are 1,3,5-triphenylbenzene 
(Compound 1); 1,3,5-tris(4-fluorophenyl)benzene (Compound 2); 1,3,5-tris(4-nitrophenyl)benzene 
(Compound 3); 1,3,5-tris(4-methylphenyl)benzene (Compound 4); 1,3,5-tris(4-
methoxyphenyl)benzene (Compound 5); and 1,3,5-tris(4-hydroxyphenyl)benzene (Compound 6). 
H6P2W18O62/nanoclinoptilolite
R:
Compound 1: H; 1,3,5-Triphenylbenzene
Compound 2: 4-F; 1,3,5-Tris(4-fluorophenyl)benzene
Compound 3: 4-NO2; 1,3,5-Tris(4-nitrophenyl)benzene
Compound 4: 4-Me; 1,3,5-Tris(4-methylphenyl)benzene
Compound 5: 4-OMe; 1,3,5-Tris(4-methoxyphenyl)benzene
Compound 6: 4-OH; 1,3,5-Tris(4-hydroxyphenyl)benzene
Compounds 1-6
O
3 H2O+3 solvent free, 100 ºC
R
R
R
R
 
Scheme 1. General formulation for the cyclotrimerization of acetophenones. 
The names and chemical formulas of the six compounds are reported in Scheme 1. Their NMR 
spectra are reported in the supplementary information, again along with their chemical formulas 
(Figures S1–S6). 
2.2. Effect of 1,3,5-Triarylbenzenes and Their Derivatives on Heat-Induced Fibrillation of HEWL Monitored 
with ThT Fluorescence 
The inhibition potential of the six compounds was determined using the ThT fluorescence assay 
to measure the amount of amyloid aggregates after the addition of various concentrations of each 
compound ranging from 0.03 to 2.6 µM. Aggregation of HEWL was induced by incubating the 
protein for 48 h at a concentration of 2 mg/mL (140 µM) in 50 mM glycine buffer, pH 2.5, and 57 °C, 
while stirred gently by magnetic bars (rpm 250), in the absence or presence of 0.03–2.6 µM 
compounds 1–6. All compounds clearly showed a pattern of dose-dependent inhibition, as suggested 
by the observed decrease of ThT fluorescence intensity (Figure 1). The IC50 values of the compounds, 
corresponding to the concentration at which the inhibitory effect is half of the maximum effect, were 
determined (Figure 2). The relative order of efficacy of the compounds in terms of IC50 value is 
compound 2 > compound 1 > compound 3 ~ compound 5 > compound 4 > compound 6 and, thus, 
compound 2 is the best inhibitor and compound 6 has minimum effect in this process. As shown in 
Figures 1 and 2, 0.32 µM of all compounds significantly inhibited the aggregation of HEWL, thus this 
concentration was used for the subsequent experiments. 
A control experiment was also designed to rule out the possibility that the low ThT fluorescence 
intensities measured in the presence of these compounds might result from the quenching of ThT 
fluorescence by the compounds themselves. These compounds were separately added at final 
concentrations of 2.6 µM to pre-formed HEWL aggregates and the ThT fluorescence assay was 
performed immediately before and after compound addition. The ThT fluorescence values were 
found to be similar in each case, before and after compound addition, indicating the lack of any 
significant quenching effect (Figure S7). 
Scheme 1. General formulation for the cyclotrimerization of acetophenones.
The names and chemical formulas of the six compounds are reported in Scheme 1. Their NMR
spectra are reported in the supplementary information, again along with their chemical formulas
(Figures S1–S6).
2.2. Effect of 1,3,5-Triarylbenzenes and Their Derivatives on Heat-Induced Fibrillation of HEWL Monitored
with ThT Fluorescence
The inhibition potential of the six compounds was determined using the ThT fluorescence assay
to measure the amount of myloid aggregates after the addition of various concentrations of each
c mpound ranging from 0.03 to 2.6 µM. Ag regation of HEWL was induced by incubating the protein
for 48 h at a concentration of 2 mg/mL (140 µM) in 50 mM glycine buffer, pH 2.5, and 57 ◦C, whil
stirred gently by m gnetic bars (rpm 50), in the absence or presence of 0.03–2.6 µM compounds 1–6.
All compounds clearly showed a pattern of dose-dependent inhibition, as sugg sted by the observed
decrease of ThT fluorescence intensity (Figure 1). The IC50 valu s of the compounds, corresponding
to the concentration at which the inhibitory effect is half of the maximum effect, wer determi ed
(Figure 2). The relative order of efficacy of the compounds in terms of IC50 value is compound 2 >
compou d 1 > compound 3 ~ compound 5 > compound 4 > compound 6 a d, thus, compound 2 is
the best inhibitor and compound 6 has minimum effect in this process. As shown in Figures 1 and 2,
0.32 µM of all compounds significantly inhibite the aggregation of HEWL, thus this concentratio
was used for the subsequent experiments.
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Figure 1. Dose-dependent inhibition of 0.03–2.6 µM compounds 1–6 on hen egg white lysozyme
(HEWL) amyloid fibril formation at 2 mg/mL (140 µM), in 50 mM glycine buffer, pH 2.5, and 57 ◦C,
under stirring (250 rpm), for 48 h, monitored by changes in thioflavin T (ThT) florescence intensity.
The spectra refer to ThT alone (gray), HEWL pre-incubated with 0 (black), 0.03 (violet), 0.06 (indigo),
0.08 (dark blue), 0.16 (blue), 0.32 (green), 0.65 (yellow), 1.3 (orange), and 2.6 (red) µM of compounds 1–6.
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Figure 2. Concentration-dependent prevention of HEWL amyloid fibril formation by compounds 1–6
incubated as described in Figure 1 at different compound concentrations, ranging from 0.03 to 2.6 µM.
The traces refer to compound 1 (red), compound 2 (orange), compound 3 (yellow), compound 4 (green),
compound 5 (blue), and compound 6 (indigo). The dotted line indicates a level of 50%.
A control experiment was also designed to rule out the possibility that the low ThT fluorescence
intensities measured in the presence of these c mpounds might res lt from the quenching of ThT
fluoresc ce by the compounds themselves. These compounds were separately added at final
concentrations of 2.6 µM to pre-formed HEWL aggregates and the ThT fluorescence assay was
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performed immediately before and after compound addition. The ThT fluorescence values were found
to be similar in each case, before and after compound addition, indicating the lack of any significant
quenching effect (Figure S7).
2.3. Effect of 1,3,5-Triarylbenzenes and Their Derivatives on Heat-Induced Fibrillation of HEWL Monitored
with CR Assay
Aliquots of the same samples used for ThT experiments were also used to carry out the CR
assays. The CR absorbance measured in the absence of HEWL and any of the compounds was found
to be low, with a peak at 490 nm (Figure 3A). The CR absorbance measured in the presence of HEWL
pre-incubated for 48 h under aggregating conditions in the absence of any compound exhibited a weak
increase accompanied by a red shift of the peak to 520–540 nm (Figure 3A). The higher CR absorbance
obtained in the presence of HEWL is likely to originate from the presence of protein aggregates that
scatter light, whereas the red shift of the peak from 490 to 520–540 nm indicates the presence of β-sheet
containing aggregates. The CR absorbance measured in the presence of HEWL pre-incubated for 48 h
under aggregating conditions with 0.32 µM compounds 1, 2, 3, 4, and 5 were found to be lower than
that measured in the absence of the compounds (Figure 3A). This indicates that these compounds were
able to inhibit HEWL amyloid fibril formation. The CR absorbance measured in the presence of HEWL
and 0.32 µM compound 6 was found to be markedly higher, with a higher red shift, indicating that this
compound was not effective in inhibiting HEWL amyloid formation. These results were confirmed
by analyzing the difference spectra, obtained by subtracting in each case the spectrum of CR alone
from those obtained with HEWL aggregates and CR (Figure 3B). The absorbance peak at 540 nm,
obtained without compounds 1–6 and readily assigned to CR bound to the aggregates, was found
to be suppressed in the presence of the various compounds 1–5, with only a modest decrease in the
presence of compound 6.
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Figure 3. Effects of compounds 1–6, at a concentration of 0.32 µM, on HEWL aggregation at 2 mg/mL,
50 mM glycine buffer, pH 2.5, 57 ◦C, under stirring (250 rpm), monitored by changes in CR absorbance
after 48 h. (A) The spectra refer to CR alone (gray), HEWL pre-incubated under aggregating conditions
without compounds (black), with compound 1 (red), compound 2 (orange), compound 3 (yellow),
compound 4 (green), compound 5 (blue), and compound 6 (indigo). (B) Difference spectra obtained by
subtracting the spectrum of CR alone from the spectra of HEWL aggregates with CR reported in (A).
Color code as in (A).
In this study, we used dimethyl sulfoxide (DMSO) for dissolving our compounds, and, thus, a
control experiment was carried out to determine whether DMSO itself had an effect on the HEWL
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aggregation. However, 2% (v/v) DMSO used here has a minimal effect on the aggregation of HEWL
(Figure S8). Therefore, all compounds were dissolved in DMSO prior to use.
The results observed by the ThT and CR assay depicted in Figures 1–3 could be due to an ability
of the six compounds to inhibit HEWL aggregation. Alternatively, they might just inhibit amyloid
fibril formation without preventing the formation of protein aggregates with a non-amyloid structure.
To assess either possibility, we centrifuged the various HEWL samples and measured the protein
concentration of the resuspended pellets, showing that pellets obtained from samples preincubated with
compounds 1–6 had a higher protein content than those incubated without compounds. This indicated
that the aromatic molecules did not inhibit aggregation of HEWL generally, but more specifically its
process of amyloid fibril formation.
2.4. Effect of 1,3,5-Triarylbenzenes and Their Derivatives on Heat-Induced Fibrillation of HEWL Monitored
with FTIR Spectroscopy
New samples of HEWL aggregates with or without compounds 1–6 at a concentration of 0.32 µM
were prepared, under the same conditions as those used for ThT and CR experiments, centrifuged
after 48 h to collect the aggregates, resuspended at high concentration in D2O and analyzed with FTIR
spectroscopy, to determine the effects of the six compounds on the secondary structure of the HEWL
aggregates. The HEWL aggregates without compounds showed a clear maximum at 1624 ± 1 cm−1
in the amide I region of the FTIR spectrum, which can readily be assigned to intermolecular β-sheet
structure (Figure 4). Another peak is present at ca. 1650 cm−1 attributable to either unordered or
α-helical secondary structure. All the HEWL aggregates formed in the presence of the compounds
showed a lower absorbance peak at 1623–1625 cm−1 and a higher absorption at 1648–1652 cm−1,
indicating loss of β-sheet structure and gain of other types of secondary structure in the aggregates
(Figure 4). In particular, compound 2 led to the most remarkable change, followed by compound 1,
compound 4, compound 3, compound 5, and compound 6, a ranking similar to that observed with
ThT fluorescence.
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2.5. Effect of the Compounds on the Kinetic of HEWL Aggregation
The time course of HEWL amyloid fibril formation in the absence of the compounds monitored
by measuring the ThT fluorescence emission intensity over a period of 48 h was nucleation dependent,
with a typical sigmoidal profile, including lag, exponential, and equilibrium phases [8]. This kinetic
trace was meant to be qualitative rather than quantitative and, for this reason, data were acquired only
every 6 h until 48 h. Inhibition of amyloid aggregation by the various inhibitors is generally quantified
by assessing changes of the lag time, exponential phase, and aggregation extent at equilibrium plateau.
The lag times measured in the presence of compounds 1–5, thus except compound 6, was relatively
long (Figure 5). In addition, in presence of all compounds, again except compound 6, the exponential
phase changed but with different magnitudes (Figure 5).
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under stirring (250 rpm), in the presence f . ounds 1–6 followed by monitoring hT
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2.6. Effect of the Compounds on HEWL Aggregation orphology
In order to define further the nature of t t species, an analy is of their morphologies
was carried out sing AFM. HEWL was incubated under the same ag regation condit ons used for the
ThT, CR, and FTIR experiments, i.e., for 48 h at a concentration of 2 mg/mL (140 µM) in 50 mM glycine
buffer, pH 2.5, and 57 ◦C, under stirri g (250 pm), in the abse ce or pr sence of 0.32 µM of compounds
1–6 and the resulting sampl s were examined by AFM (Figure 6). HEWL aggregates in the abs nce of
compounds showed typical long, unbranched fibrils. On the other hand, when HEWL as incubated
in presence of compounds 1–4, very few fibrils were observed after 48 h. Rather, oligomeric and/or
amorphous species were predominant. HEWL pre-incubated in presence of compound 5 showed a
few short fibrillar assemblies along with oligomeric species and, in the presence of compound 6, a
mixture of unbranched filamentous assemblies appeared. These results again showed that compound
6 cannot inhibit the formation of HEWL aggregates in agreement with the ThT and CR results.
2.7. Effect of the Compounds on HEWL Amyloid Induced Cytotoxicity
We then assessed the cytotoxicity of HEWL aggregates, formed in the absence or presence of
compounds 1–6, according to the aggregation protocol described for the ThT experiments. HEWL
aggregates were collected by centrifugation, dried under N2, dissolved in cell culture medium, and
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added to SH-SY5Y human neuroblastoma cells at a concentration of 2 µM (monomer equivalents).
The ability of the resulting aggregates to cause cellular dysfunction was assessed by performing the
MTT reduction inhibition assay, a widely used indicator of mitochondrial dysfunction [45]. The ability
of SH-SY5Y cells to reduce MTT was significantly decreased to 73.9 ± 2.1% (relative to untreated cells)
after a 24 h exposure to HEWL aggregates, whereas it was unaffected by native HEWL treatment
(Figure 7A). The ability of cells to reduce MTT was significantly increased when HEWL aggregates
were formed in the presence of compound 1 (to 92.7 ± 3.2%), 2 (to 96.2 ± 3.2%) and 5 (to 93.9 ± 2.9%).
By contrast, incubation with compounds 3, 4, and 6 resulted in a partial rescue of the cell viability.
Very similar results were obtained by measuring the activity of caspase-3, a well-recognized apoptotic
marker [46]. A significant activation of caspase-3 (320 ± 12%, as compared to untreated cells) was
observed following treatment for 24 h of SH-SY5Y cells with HEWL aggregates at 2 µM (Figure 7B).
Moreover, the presence of compounds 1, 2, 4, and 5 during HEWL aggregation significantly prevented
the apoptotic response induced by aggregates (Figure 7B). Furthermore, in this case, compounds 3 and
6 generated only a slight protective effect on apoptotic pathway activation.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 19 
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3. Discussion
Design and synthesis of novel small-compound inhibitors of the process of amyloid fibril formation
is one of the leading therapeutic approaches for the treatment of amyloid diseases [47–50]. The studies
on different amyloidogenic proteins showed that small aromatic compounds are able to inhibit fibril
formation, possibly due to their ability to interfere with the β-sheet architecture of the fibrils and/or
aromatic stacking in fibril stabilization [22,30,51,52]. In fact, the exact contribution of aromaticity to
amyloid formation is controversial and remains under debate [53].
Various findings demonstrate that the functional groups appended to the aromatic rings [54,55],
geometry and steric profile of the functional groups on the aromatic rings [53], and also
number of rings [36] can dramatically affect amyloid formation. We have recently reported that
bis(indolyl)phenylmethane compounds inhibited the formation of amyloid fibrils and associated
toxicity in a concentration-dependent manner [33]. We also showed that all tested compounds
were able to inhibit HEWL amyloid fibril formation but with different efficiencies, which showed
the importance of slight variations of the functional groups within the same scaffold as a small
molecule [33].
In this work, a series of novel 1,3,5-triarylbenzenes derivatives having four aromatic rings and
different electron-donor or -acceptor substitutions were synthesized and evaluated for their potential
to prevent HEWL amyloid aggregation. These compounds, similar to bis(indolyl)phenylmethanes
studied previously, were shown to inhibit HEWL amyloid fibril formation under conditions in which
the protein is initially partially unfolded, but with different magnitude. In particular, considering the
various techniques used here, including the ThT and CR assays, AFM, and FTIR, compounds 1–3 were
found to be clearly more effective as inhibitors in comparison to compounds 4–6, particularly the latter
that did not show any detectable effect (Figures 1–5). These findings showed that electron-donating
substituents have less efficacy in preventing HEWL amyloid formation, whereas electron-withdrawing
groups have much more influence in amyloid inhibition. The IC50 values of the compounds were
between 0.05 and 0.98 µM, which are two orders of magnitude lower than the IC50 value measured by
a representative bis(indolyl)phenylmethane, i.e., 12.3 ± 1 µM [33].
The amorphous and unstructured HEWL aggregates formed in the presence of all compounds were
less toxic than the HEWL fibrils formed in their absence, as shown by MTT cell viability and caspase
activity assays (Figure 7). Moreover, our results showed that HEWL aggregates formed in the presence
of 1,3,5-triarylbenzenes derivatives, similar to results obtained with bis(indolyl)phenylmethane [33]
and curcumin [56] derivatives, were non-toxic or retain a weak toxicity, allowing all these compounds to
be classified as class I molecules, based on the classification proposed by Ladiwala et al., i.e., molecules
that remodel soluble oligomers into species (often large off-pathway aggregates) that are non-toxic [57].
It has been proposed that pi–pi stacking of aromatic rings can be enhanced when two rings are
electron poor and rich, respectively [36]. Our work and results presented by other scientists [36] are in
agreement with this theory, as the addition of a strong electron-withdrawing group, such as –NO2, –F,
or –CN [36] on the aromatic inhibitor increases the inhibitory effect, possibly due to the formation of a
strong electron donor–electron acceptor complex between the inhibitory compounds and the aromatic
residues of HEWL. In particular, the –F group was found to be the most effective, probably due to its
high electronegativity, followed by the –NO2 group. On the other hand, when an electron-donating
group, such as a –OH, –CH3, or –OCH3, was added, amyloid inhibition is decreased due to a repulsion
between the electron-rich aromatic ring of the inhibitor and the electron-rich aromatic residues of
HEWL, which does not allow the establishment of a stable complex between the inhibitor and the
protein undergoing aggregation. In this context, the –OH group is the least effective in inhibiting
HEWL aggregation.
Inhibitory effects of bis(indolyl)phenylmethanes may be discussed from different points of
view, including different factors, such as the importance of inter- and intra-molecular hydrogen
bonds, electronic effects and steric hindrances, the intrinsic steric congestion originating from the
structural framework of bis-indolylarylmethanes, all affected by the substituents. In the case of
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1,3,5-triarylbenzenes, a fully planar formula presents three aryl substituents in the same plane as
the central benzene ring. In this case, only the aryl substituents may exert a little steric congestion
around the aryl rings. Therefore, the net structure should have a planar identity and we can assume
an effective diffusion of these types of compounds into amyloid fibrils. This can explain both the
most effective inhibitory potential of 1,3,5-triarylbenzenes relative to bis-indolylarylmethanes and the
critical role played by the electron releasing/donating substituents on the aryl rings in determining
such an inhibition.
4. Materials and Methods
4.1. Materials
Hen egg white lysozyme (HEWL), thioflavin T (ThT), and Congo red (CR) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Other reagents were purchased from Merck (Darmstadt, Germany),
unless stated otherwise. All synthesized molecules were compared, in terms of their spectral and
physical data, with those reported previously [58].
4.2. General Chemistry
All reagents and starting materials were commercially available and were used as received.
Natural clinoptilolite-rich tuffs were obtained from the Sabzevar region in the north-east of Iran.
Fourier-transform infrared (FT-IR) spectra were recorded on a 8700 Shimadzu Fourier-transform
spectrophotometer (Shimadzu, Tokyo, Japan) in the region of 400–4000 cm−1 using KBr pellets. 1H and
13C NMR spectra were recorded on a Bruker AVANCE 300 MHz instrument (Bruker, MA, USA) using
TMS as internal reference. All products were identified by comparison of their spectral and physical data
with those previously reported. Wells–Dawson diphosphooctadecatungstic acid H6P2W18O62·24H2O
was prepared according to the literature method [59].
General Procedure for the Conversion of Acetophenone into 1,3,5-Triphenylbenzene
In a typical reaction, acetophenone (1 mmoL) and the surface-modified HPA/NCP (15 mg) were
added to a small test tube and the reaction mixture was stirred for 2.5 h at 100 ◦C. After completion
of the reaction, as indicated by thin layer chromatography (TLC), the reaction mass was cooled to
25 ◦C; then, hot ethanol was added to the reaction mixture and the mixture was stirred for 5 min.
The insoluble catalyst was isolated via simple filtration. The filtrate containing water as the only
byproduct of the cyclotrimerization was concentrated under reduced pressure, and finally the obtained
crude product was purified through re-crystallization in EtOH:H2O (3:1) as confirmed by an intense
single spot in TLC. The pure products were specified based on the spectral data and determination of
their melting points.
1,3,5-Triphenylbenzene (Compound 1)
Light yellow solid; m. p. 171–173 ◦C. IR (KBr): vmax = 3053, 1651, 1494, 1431, 1125, 758, 700 cm−1.
1H NMR (DMSO-d6, 500 MHz): δ 7.88 (s, 3H), 7.87–7.86 (m, 6H), 7.52–7.49 (t, J = 7.5 Hz, 6H), 7.43–7.40
(t, J = 7.5 Hz, 3H).13C NMR (DMSO-d6, 125 MHz): δ 141.6, 140.1, 128.9, 127.7, 127.2, 124.4.
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1,3,5-Tris(4-Fluorophenyl)Benzene (Compound 2)
White solid; m. p. 238–240 ◦C. IR (KBr): vmax = 3059, 1604, 1508, 1449, 1224, 1159, 825, 771 cm−1.
1H NMR (CDCl3, 500 MHz): δ 7.67 (s, 3H), 7.61 (d, J = 8.5 Hz, 6H), 7.59 (d, J = 8.5 Hz, 6H). 13C NMR
(CDCl3, 125 MHz): 161.7, 137.6, 132.4, 129.0 (d, J = 7.5 Hz), 125.3, 115.9 (d, J = 22.5 Hz).
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4.2.1.3. 1,3,5-Tris(4-Nitrophenyl)Benzene (Compound 3) 1,3,5-Tris(4-Nitrophenyl)Benzene (Compound 3)
White solid; m. p. 151–152 ◦C. IR (KBr): vmax = 3043, 1595, 1489, 1379, 1085, 1007, 849 cm−1. 1H
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4.2.1.5. 1,3,5-Tris(4-Methoxyphenyl)Benzene (Compound 5) 
White solid; m. p. 142–143 °C. IR(KBr): vmax = 2953, 2918, 2848, 1598, 1460, 1378, 1263, 1097, 802 
cm−1. 1H NMR (CDCl3, 500 MHz): δ 7.59 (d, J = 9.0 Hz, 6H), 7.37 (s, 3H), 6.99 (d, J = 8.5 Hz, 6H), 3.86 
(s, 9H). 13C NMR (CDCl3, 125 MHz): 159.7, 141.7, 134.0, 129.3, 122.7, 114.2, 55.9. 
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4.2.1.6. 1,3,5-Tris(4-Hydroxyphenyl)Benzene (Compound 6) 
White solid; m. p. 237–239 °C. IR (KBr): vmax = 2953, 2918, 2848, 1606, 1460, 1378, 1263, 1097, 802 
cm−1. 1H NMR (CDCl3): δ = 3.81 (s, 9H), 6.94–7.41 (m, 12H), 7.79 (s, 3H). 13C NMR (CDCl3, 125 MHz): 
δ 55.4, 114.3, 123.8, 128.3, 133.9, 141.8, 159.3. 
1,3,5-Tris(4-Methylphenyl)Benzene (Compound 4)
White solid; m. p. 178–179 ◦C. IR (KBr): vmax = 3017, 2922, 1612, 1511, 1491, 1109, 812 cm−1. 1H
NMR (CDCl3, 500 MHz): δ 7.74 (s, 3H), 7.62 (d, J = 8.0 Hz, 6H), 7.30 (d, J = 7.5 Hz, 6H), 2.44 (s, 9H). 13C
NMR (CDCl3, 125 MHz): 142.2, 138.3, 137.4, 129.4, 127.3, 124.7, 21.1.
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White solid; m. p. 237–239 °C. IR (KBr): vmax = 2953, 2918, 2848, 1606, 1460, 1378, 1263, 1097, 802 
cm−1. 1H NMR (CDCl3): δ = 3.81 (s, 9H), 6.94–7.41 (m, 12H), 7.79 (s, 3H). 13C NMR (CDCl3, 125 MHz): 
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1,3,5-Tris(4-Methoxyphenyl)Benzene (Compound 5)
; . p. 142–143 ◦C. IR(KBr): vmax = 2953, 291 , 2848, 1598, 1460, 1378, 1263, 1097,
802 cm−1. 1H NMR (CDCl3, 500 MHz): δ 7.59 (d, J = 9.0 z, 6H), 7.37 (s, 3H), 6.99 (d, J = 8.5 z, 6H),
3.86 (s, 9H). 13C NMR (CDCl3, 125 MHz): 159.7, 141.7, 134.0, 129.3, 122.7, 114.2, 55.9.
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4.3. Protein Aggregation 
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HEWL was dissolved to a concentration of 2 mg/mL (140 µM) in 50 mM glycine buffer, pH 2.5, 
centrifuged for 10 min at 13,000 rpm, then incubated at 57 °C for the specified time lengths in the 
absence or presence of the indicated concentrations of compounds 1–6, under gentle stirring at 250 
rpm by a Teflon magnetic bar [33]. 
4.4. ThT Fluorescence Assay 
A mother solution of 2.5 mM ThT was prepared in 10 mM sodium phosphate buffer, 150 mM 
NaCl, pH 7.0. It was then passed through a 0.45 µm filter paper and stored at 4 °C until it was placed 
at room temperature immediately before use. At regular time intervals, a 10 µL aliquot of protein 
solution was mixed with 990 µL of ThT solution in a 10 × 10 mm quartz cuvette and the fluorescence 
emission spectra were recorded at room temperature using a Cary Eclipse VARIAN fluorescence 
spectrophotometer (Varian, Mulgrave, Australia) and an excitation wavelength of 440 nm [61]. 
4.5. CR Assay 
Since compounds 1–6 have optical absorption spectra partially overlapped to that of CR, all 
protein samples were centrifuged at 10,000 rpm and the pellets resuspended in 50 mM glycine buffer, 
pH 2.5, at room temperature. A mother solution of 20 mM CR was prepared in 5 mM sodium 
phosphate buffer, 150 mM NaCl, pH 7.4, it was then filtered using a center-glass N4 filter and stored 
at 4 °C, until it was placed at room temperature immediately before use. At different time points 
during protein aggregation, a 60 µL aliquot of resuspended protein solution was mixed with 440 µL 
of CR solution. Optical absorption spectra were acquired after 2–3 min equilibration at 25 °C, using 
a Cecil 7200 UV–visible spectrophotometer (Aquarius, Cambridge, England) and a 1 cm path-length 
cell. 
4.6. FTIR Spectroscopy  
Samples were incubated for 48 h to promote aggregation as described above in the presence of 
0.32 µM compounds 1–6, centrifuged at 13,000× g for 10 min and resuspended in D2O to a final 
volume of 72.8 µL, to reach a final concentration of 27.8 mg/mL. For each sample, 40 µL was deposited 
onto an Omni-Cell transmission cell with a 25 µm spacer (Specac, Orpington, UK), and Fourier-
transform infrared (FTIR) spectra were recorded using a FTS-40 FTIR spectrometer (Bio-Rad, 
Hercules, CA, USA) purged with a continuous flow of dry air. Sixty-four interferograms were 
accumulated in each case at a spectral resolution of 1 cm−1. The FTIR absorbance spectra were blank-
subtracted and baseline-corrected to reveal the amide I region (1600–1700 cm−1). For each spectrum, 
the sharp water peaks in the amide I and flanking regions (1580–1800 cm−1) were eliminated by using 
a multiple Gaussian function to fit only the experimental data that were devoid of such peaks in this 
region and replotting the spectrum as the best fitted function. All spectra were normalized to the 
same amide I region area. Additional smoothing was not carried out. 
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Since compounds 1–6 have optical absorption spectra partially overlapped to that of CR, all
protein samples were centrifuged at 10,000 rpm and the pellets resuspended in 50 mM glycine buffer,
pH 2.5, at room temperature. A mother solution of 20 mM CR was prepared in 5 mM sodium phosphate
buffer, 150 mM NaCl, pH 7.4, it was then filtered using a center-glass N4 filter and stored at 4 ◦C, until
it was placed at room temperature immediately before use. At different time points during protein
aggregation, a 60 µL aliquot of resuspended protein solution was mixed with 440 µL of CR solution.
Optical absorption spectra were acquired after 2–3 min equilibration at 25 ◦C, using a Cecil 7200
UV–visible spectrophotometer (Aquarius, Cambridge, England) and a 1 cm path-length cell.
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4.6. FTIR Spectroscopy
Samples were incubated for 48 h to promote aggregation as described above in the presence of
0.32 µM compounds 1–6, centrifuged at 13,000× g for 10 min and resuspended in D2O to a final volume
of 72.8 µL, to reach a final concentration of 27.8 mg/mL. For each sample, 40 µL was deposited onto
an Omni-Cell transmission cell with a 25 µm spacer (Specac, Orpington, UK), and Fourier-transform
infrared (FTIR) spectra were recorded using a FTS-40 FTIR spectrometer (Bio-Rad, Hercules, CA, USA)
purged with a continuous flow of dry air. Sixty-four interferograms were accumulated in each
case at a spectral resolution of 1 cm−1. The FTIR absorbance spectra were blank-subtracted and
baseline-corrected to reveal the amide I region (1600–1700 cm−1). For each spectrum, the sharp water
peaks in the amide I and flanking regions (1580–1800 cm−1) were eliminated by using a multiple
Gaussian function to fit only the experimental data that were devoid of such peaks in this region and
replotting the spectrum as the best fitted function. All spectra were normalized to the same amide I
region area. Additional smoothing was not carried out.
4.7. Atomic Force Microscopy
HEWL samples pre-incubated for 48 h under aggregating conditions with or without 0.32 µM
compounds 1–6 were diluted 100 times in filtered deionized water. A 5 µL aliquot of each of the
resulting samples was placed on freshly cleaved mica at room temperature. After a few minutes, the
mica was slowly washed with 100 µL of deionized water and dried with N2. Each image was acquired
in a non-contact mode at a scan speed of 30 µm/s, loop filter of 3 Hz and force of 200 nN with a Dual
Scope Probe Scanner (Veeco, model Auto probe, CP-Research, CA, USA) with an area of 5 × 5 µm2.
Conical shape silicon tips (MikroMasch NSC16) with a resonance frequency of 150 kHz and a nominal
constant of 40 N/m were used. Fifteen images were collected for each compound.
4.8. Cell Cultures
Authenticated human neuroblastoma SH-SY5Y cells were purchased from American Type Culture
Collection (ATCC) (Manassas, VA, USA) and they tested negative for mycoplasma contaminations.
SH-SY5Y cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM), F-12 Ham with 25 mM
HEPES and NaHCO3 (1:1) supplemented with 10% fetal bovine serum (FBS), 1.0 mM glutamine and
1.0% penicillin and streptomycin solution. Cells were maintained in a 5.0% CO2 humidified atmosphere
at 37 ◦C and grown until 80% confluence for a maximum of 20 passages.
4.9. 3-(4,5-Dimethylthiazol)-2,5-Diphenyltetrazolium Bromide (MTT) Reduction Test
HEWL samples pre-incubated for 48 h under aggregating conditions in the absence or presence
of 0.32 µM compounds 1–6 were centrifuged and the pellets were dried under N2 to remove any
compounds and DMSO, dissolved in cell culture medium at a final HEWL concentration of 2 µM
(monomer equivalents), and added to SH-SY5Y cells seeded in 96-well plates for 24 h at 37 ◦C. The cell
medium was then removed and the MTT solution (0.5 mg/mL in RPMI) was added to the cells for 4 h.
The medium was then aspirated, and the formazan product was solubilized with cell lysis buffer (20%
SDS, 50% N, N-dimethylformamide, pH 4.7) for 1 h, as previously described [62].
4.10. Measurement of Caspase-3 Activity
HEWL aggregates were formed in the absence or in the presence of 0.32 µM of compounds 1–6 as
described in the previous section and then added to the cell culture medium of SH-SY5Y cells seeded on
glass coverslips for 24 h at 2 µM (monomer equivalents). Caspase-3 activity was then analyzed by using
FAM FLICATM caspases 3 & 7 solution (caspase 3 & 7 FLICA kit FAM-DEVDFMK, Immunochemistry
Technologies, LLC, Bloomington, MN, USA). Cell fluorescence was analyzed by the TCS SP8 scanning
confocal microscopy system (Leica Microsystems, Mannheim, Germany) equipped with an argon laser
source, as previously reported [62]. A series of 1.0 µm thick optical sections (1024 × 1024 pixels) was
Int. J. Mol. Sci. 2019, 20, 5558 15 of 18
taken through the cell depth for each sample using a Leica Plan Apo 63 × oil immersion objective
for fluorescence measurement at 488 nm. The confocal microscope was set at optimal acquisition
conditions, e.g., pinhole diameters, detector gain, and laser powers. Settings were maintained constant
for each analysis.
4.11. Statistical Analysis
All data were expressed as means ± standard error of mean (S.E.M). ANOVA followed by
Bonferroni’s post comparison test was used to compare different values.
5. Conclusions
In conclusion, we have provided experimental evidence of different effects of various substituents
of the architecture of the 1,3,5-triarylbenzene molecule on the inhibition of the self-assembly of HEWL.
We showed that –OH, –OCH3, and –CH3 groups as electron-donor groups positioned on aromatic
rings have a low efficacy, whereas –F and –NO2 as electron-withdrawing groups have great efficacy in
inhibiting amyloid formation by HEWL. Based on the results of this study and others, it is apparent
that small aromatic compounds and functional groups appended on these aromatic molecules can
have a profound effect on their ability to inhibit amyloid formation. These results may ultimately
find applications in the development of potential amyloid inhibitors and, thus, possible use of these
compounds as a therapeutic approach in the treatment of amyloid deposition diseases.
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Abbreviations
HEWL hen egg white lysozyme
ThT thioflavin T
HPA/NCP H6P2W18O62/nanoclinoptilolite
CR Congo red
AFM atomic force microscopy
FTIR Fourier-transform infrared spectroscopy
MTT 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide
NMR nuclear magnetic resonance
TLC thin layer chromatography
DMSO dimethyl sulfoxide
mp melting point
DMEM Dulbecco’s modified Eagle’s medium
PBS phosphate buffered saline
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